Table 2. Immune responses to V. cholerae (O1 Ogawa and O1 Inaba) following vaccination with BivWC.
| Total ASC | O1 Ogawa | O1 Inaba | |||
|---|---|---|---|---|---|
| Day 0 (n = 22) | |||||
| Baseline Vibriocidal GMTa (95% CI) | 35.3 | (15.1–82.2) | 29.2 | (14.7–58.1) | |
| Baseline Serum OSP IgA GMTb (95% CI) | 65.8 | (52.6–82.4) | 60.7 | (49.6–74.3) | |
| Baseline Total IgA ASCs | 334.5 (237.4–431.6) | ||||
| Baseline OSP IgA ASCs (per million) | 0.02 | (-0.02–0.07) | 0.07 | (-0.01–0.15) | |
| Baseline Total IgG ASCs | 920.4 (680.6–1160.1) | ||||
| Baseline OSP IgG ASCs (mean, per million) | 0.045 | (-0.020–0.11) | 0.045 | (-0.049–0.14) | |
| Day 7 (n = 22) | |||||
| Vibriocidal GMTa (95% CI) | 256.7 | (146.0–451.2) | 264.9 | (150.9–464.9) | |
| Vibriocidal GMFb (95% CI) | 7.3 | (3.4–15.6) | 9.1 | (4.9–16.9) | |
| Vibriocidal Seroconversionc (#, %) | 14 | 64 | 16 | 73 | |
| Serum OSP IgA GMTa (95% CI) | 93.6 | (66.1–132.7) | 86.6 | (64.0–117.3) | |
| Serum OSP IgA GMFb (95% CI) | 1.4 | (1.0–1.9) | 1.4 | (1.1–1.9) | |
| Serum OSP IgA Seroconversiond (#, %) | 7 | 32 | 4 | 18 | |
| Total IgA ASCs | 290 (233.5–346.5) | ||||
| OSP IgA ASCs (mean, per million) | 6.9 | (1.9–12.0) | |||
| OSP IgA ASCs Responderse (#, %) | 13 | 59 | |||
| Total IgG ASCs | 1017 (666.7–1367.3) | ||||
| OSP IgG ASCs (mean, per million) | 1.2 | (0.58–1.87) | 0.36 | (-0.0059–0.73) | |
| OSP IgG ASCs Responderse (#, %) | 5 | 22.7 | 3 | 13.6 | |
| Day 21 (n = 21) | |||||
| Vibriocidal GMTa (95% CI) | 165.4 | (81.0–333.6) | 245.7 | (141.7–426.3) | |
| Vibriocidal GMFb (95% CI) | 4.9 | (2.5–9.6) | 9.1 | (4.6–18.2) | |
| Vibriocidal Seroconversionc (#, %) | 16 | 76 | 17 | 81 | |
| Serum OSP IgA GMTa (95% CI) | 86.4 | (66.0–113.1) | 83.5 | (65.6–106.5) | |
| Serum OSP IgA GMFb (95% CI) | 1.4 | (1.1–1.9) | 1.5 | (1.2–1.8) | |
| Serum OSP IgA Seroconversiond (#, %) | 8 | 38 | 6 | 29 | |
| Total IgA ASCs | 408.3 (306.9–509.7) | ||||
| OSP IgA ASCs (mean, per million) | 1 | (0.1–1.9) | 0.8 | (0.1–1.5) | |
| OSP IgA ASCs Responderse (#, %) | 5 | 23.8 | 5 | 23.8 | |
| Total IgG ASCs | 1035.1 (786.3–1283.9) | ||||
| OSP IgG ASCs (mean, per million) | 0.41 | (-0.083–0.90) | 0.2 | (-0.091–0.50) | |
| OSP IgG ASCs Responderse (#, %) | 1 | 4.8 | 1 | 4.8 |
a Geometric mean titer.
b Geometric mean-fold rise from baseline to 7 days after 1st dose or from baseline to 7 days after 2nd dose.
c # with ≥ 4-fold rise in titers from baseline to 7 days after 1st dose or from baseline to 7 days after 2nd dose.
d 3 with ≥ 2-fold rise in titers from baseline to 7 days after 1st dose or from baseline to 7 days after 2nd dose.
e # with ≥ 2 ASCs detected
# Number of participants